Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $30

Benzinga · 2d ago
Mizuho analyst Joseph Catanzaro maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $24 to $30.